Zevra Therapeutics, Inc. (NASDAQ:ZVRA - Get Free Report) has been assigned a consensus rating of "Buy" from the nine ratings firms that are presently covering the firm, MarketBeat.com reports. Eight investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. The average twelve-month price target among brokerages that have covered the stock in the last year is $22.29.
A number of research analysts recently commented on ZVRA shares. Canaccord Genuity Group upped their price objective on Zevra Therapeutics from $23.00 to $25.00 and gave the stock a "buy" rating in a research note on Thursday, March 13th. Citigroup restated an "outperform" rating on shares of Zevra Therapeutics in a research note on Wednesday, May 14th. JMP Securities set a $18.00 price target on Zevra Therapeutics in a research note on Wednesday, March 12th. Cantor Fitzgerald reissued an "overweight" rating and issued a $25.00 price target on shares of Zevra Therapeutics in a research note on Wednesday, May 14th. Finally, Wall Street Zen raised Zevra Therapeutics from a "hold" rating to a "buy" rating in a research note on Thursday, May 22nd.
Read Our Latest Stock Report on ZVRA
Zevra Therapeutics Stock Performance
Shares of ZVRA stock traded down $0.11 on Monday, hitting $8.52. 26,573 shares of the stock traded hands, compared to its average volume of 643,964. The company has a debt-to-equity ratio of 0.84, a current ratio of 2.88 and a quick ratio of 2.88. The company has a market capitalization of $465.60 million, a PE ratio of -4.31 and a beta of 1.87. Zevra Therapeutics has a 1-year low of $4.20 and a 1-year high of $9.76. The company's fifty day moving average is $7.63 and its 200 day moving average is $8.07.
Zevra Therapeutics (NASDAQ:ZVRA - Get Free Report) last posted its quarterly earnings results on Tuesday, May 13th. The company reported ($0.06) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.21) by $0.15. The business had revenue of $20.40 million for the quarter, compared to analyst estimates of $16.96 million. Zevra Therapeutics had a negative return on equity of 159.54% and a negative net margin of 342.63%. During the same period in the prior year, the company posted ($0.40) EPS. On average, equities research analysts predict that Zevra Therapeutics will post -1.95 earnings per share for the current fiscal year.
Insider Activity at Zevra Therapeutics
In other Zevra Therapeutics news, Director John B. Bode bought 10,000 shares of the firm's stock in a transaction on Wednesday, March 19th. The stock was purchased at an average cost of $7.96 per share, with a total value of $79,600.00. Following the completion of the purchase, the director now owns 40,000 shares in the company, valued at approximately $318,400. The trade was a 33.33% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. 2.40% of the stock is owned by insiders.
Institutional Inflows and Outflows
Several large investors have recently bought and sold shares of ZVRA. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in shares of Zevra Therapeutics by 6.1% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 31,761 shares of the company's stock valued at $238,000 after acquiring an additional 1,812 shares in the last quarter. IFG Advisors LLC lifted its stake in Zevra Therapeutics by 10.0% in the fourth quarter. IFG Advisors LLC now owns 29,050 shares of the company's stock valued at $242,000 after purchasing an additional 2,650 shares during the last quarter. Invesco Ltd. raised its holdings in Zevra Therapeutics by 19.6% during the 4th quarter. Invesco Ltd. now owns 18,384 shares of the company's stock valued at $153,000 after acquiring an additional 3,007 shares during the period. Corebridge Financial Inc. increased its holdings in shares of Zevra Therapeutics by 16.9% in the fourth quarter. Corebridge Financial Inc. now owns 26,294 shares of the company's stock worth $219,000 after purchasing an additional 3,801 shares during the period. Finally, Charles Schwab Investment Management Inc. grew its position in Zevra Therapeutics by 2.6% in the first quarter. Charles Schwab Investment Management Inc. now owns 153,331 shares of the company's stock worth $1,148,000 after acquiring an additional 3,827 shares in the last quarter. 35.03% of the stock is owned by institutional investors and hedge funds.
About Zevra Therapeutics
(
Get Free ReportZevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.
Read More
Before you consider Zevra Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Zevra Therapeutics wasn't on the list.
While Zevra Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
